Data of safety in a single-center alemtuzumab treated population

Alemtuzumab is approved for highly active MS and, in Europe, can be employed after other disease-modifying treatments (DMTs) as an escalation approach or first therapeutic option. The occurrence of secondary autoimmune adverse events and infections differs depending on the employed approach. In the...

Descripción completa

Detalles Bibliográficos
Autores principales: di Ioia, Maria, Di Stefano, Vincenzo, Farina, Deborah, Di Tommaso, Valeria, Travaglini, Daniela, Pietrolongo, Erika, Sensi, Stefano L., Onofrj, Marco, De Luca, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062935/
https://www.ncbi.nlm.nih.gov/pubmed/32181303
http://dx.doi.org/10.1016/j.dib.2020.105341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062935/
https://www.ncbi.nlm.nih.gov/pubmed/32181303
http://dx.doi.org/10.1016/j.dib.2020.105341

Ejemplares similares